Yamada Y, Kono N, Hanafusa T, Mineo I, Namba M, Itoh H, Kiyokawa H, Kawachi M, Yamasaki T, Tarui S
Second Department of Internal Medicine, Osaka University Medical School, Japan.
Clin Endocrinol (Oxf). 1988 Jul;29(1):29-34. doi: 10.1111/j.1365-2265.1988.tb00246.x.
Midaglizole is a new alpha 2-adrenergic blocking agent which increases insulin release from normal pancreatic islets. We studied its effect in four patients with insulinomas. In three patients oral administration of 150 mg of midaglizole caused a large increase in serum insulin and a corresponding decrease in plasma glucose. The magnitude of the response cannot exclude the possibility that midaglizole has direct beta cell stimulatory activity. Two of the three patients had operations, and their insulin responses to midaglizole became normal after removing the tumours. In contrast, midaglizole did not stimulate insulin secretion in the fourth patient. A midaglizole stimulation test might be useful in screening patients with insulinomas.
米格列唑是一种新型α2-肾上腺素能阻滞剂，可增加正常胰岛的胰岛素释放。我们研究了其对4例胰岛素瘤患者的影响。3例患者口服150毫克米格列唑后，血清胰岛素大幅升高，血浆葡萄糖相应降低。这种反应的程度不能排除米格列唑具有直接刺激β细胞活性的可能性。3例患者中的2例接受了手术，切除肿瘤后他们对米格列唑的胰岛素反应恢复正常。相比之下，米格列唑对第4例患者的胰岛素分泌没有刺激作用。米格列唑刺激试验可能有助于筛查胰岛素瘤患者。
